Professor Angus George Dalgleish, a leading British oncologist with decades of experience in cancer research, immunology, and vaccine development, has issued one of his strongest public condemnations of mRNA technology.
In testimony given on June 3, during a U.S. Senate hearing titled “Plausible Mechanisms of COVID-19 Injections Causing Cancer and Attacks on Scientific Publications and Research,” chaired by Senator Ron Johnson (R-Wisconsin) of the Permanent Subcommittee on Investigations, Dalgleish stated: “There are at least 12 mechanisms by which mRNA can insert itself into DNA and activate oncogenes,” “there is no way to control this technology,” and “its use in future vaccines should be prohibited and COVID vaccines stopped now.”
The hearing, held in the Senate’s Dirksen Building in Washington, DC, featured Dalgleish as a key witness along with other experts such as Dr. Wafik El-Deiry, Dr. Sabine Hazan, Dr. Aseem Malhotra, and Dr. Saskia Mostert.
It focused on alleged links between mRNA injections against COVID-19 and cancer risks, concerns about integration into DNA, and allegations of scientific suppression.
Dalgleish, born in 1950 and currently Founding Professor of Oncology at St George’s University, London, and Principal of the Institute for Cancer Vaccines and Immunotherapy, brings formidable credentials to the debate. He co-discovered CD4 as the main cellular receptor for HIV, has authored or co-authored more than 500 scientific publications in journals such as Nature, Science, and Cell, and has dedicated years to the development of therapeutic cancer vaccines. His work spans HIV virology, tumor immunology, and clinical oncology, with particular expertise in melanoma, prostate, and pancreatic cancer.
At the hearing, Dalgleish spoke directly from his clinical experience. He described observing stable cancers—breast, prostate, and others—that suddenly progressed aggressively after mRNA boosters against COVID-19.
He noted that colleagues worldwide are reporting the same pattern of “turbo cancers,” which he links to interference of the spike protein with tumor suppressor genes (such as p53 and BRCA), T-cell depletion, and genomic instability. He emphasized that, despite his extensive background in vaccine research—including five years on the scientific advisory board of a company developing mRNA platforms—he has concluded that this technology is inherently uncontrollable once deployed in humans.
Dalgleish has been raising these alarms for years. In interviews, parliamentary testimony, and open letters, he has cited clinical relapses in his own melanoma patients, laboratory evidence of reverse mRNA transcription, residual DNA contamination (including SV40 promoter sequences in some batches), and multiple pathways of genomic integration.
He argues that these effects disrupt normal cellular controls, potentially activating oncogenes or deactivating tumor suppressors, leading to the rapidly developing cancers now reported anecdotally by oncologists worldwide.
Her testimony on June 3, shared by Children’s Health Defense and amplified on social media, comes amid growing international scrutiny of excess mortality trends, cancer incidence in younger populations, and long-term safety data from the mRNA platform.
Dalgleish insists that standard regulatory safeguards—normally applied to gene therapies—are absent here, and that the lipid nanoparticle delivery system and the modified pseudouridine in the mRNA make precise control impossible.
These views remain highly controversial. Health regulators and large epidemiological studies maintain that mRNA vaccines against COVID-19 do not integrate into DNA in a clinically significant way, show no causal link to increased cancer rates, and have saved millions of lives by reducing severe illness. Critics have accused Dalgleish of relying on anecdotal evidence and have pointed to his past financial ties to competing vaccine platforms. Nevertheless, his status as a veteran clinician who has directly treated thousands of cancer patients—and his willingness to speak out despite professional resistance—has earned him a platform with U.S. lawmakers and the public.
Professor Dalgleish’s central message is that the mRNA platform, once hailed as a revolutionary tool for rapid vaccine development, carries risks that cannot be eliminated through engineering.
As an oncologist who has dedicated his career to fighting cancer and advancing immunotherapy, he now argues that continuing its use in vaccines represents an unacceptable threat to genomic integrity and long-term public health.
Whether his warnings prompt further independent research or are ultimately dismissed will depend on ongoing research into cancer trends, genomic sequencing of post-vaccination tumors, and transparent pharmacovigilance data. For now, one of Britain’s most experienced cancer specialists has placed the issue squarely before policymakers: the technology, he asserts, must be stopped.